1092 completed, 192 terminated, 84 active not recruiting, 82 recruiting. 566 Phase 2, 402 Phase 1, 376 Phase 3, 122 Phase 4, 45 Not applicable.
Follow Amgen: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study Evaluating Subcutaneous Versus Intravenous Blinatumomab in Newly Diagnosed Adults With B-cell Precursor Acute Lymphoblastic Leukaemia Blinatumomab, HyperCVAD - Philadelphia Chromosome Negative B-cell Precursor Acute Lymphoblastic Leukemia | Phase 3 | Not yet recruiting | Amgen | 560 | 2028-06-30 | 2026-09-15 |
| A Trial Assessing the Effectiveness of Evolocumab in Reducing the Plaque Burden in Participants With Subclinical Atheroma Evolocumab, Routine Lipid Management, Autoinjector - Coronary Artery Disease, Hypercholesterolemia | Phase 4 | Not yet recruiting | Amgen | 308 | 2027-01-31 | 2026-09-21 |
| Phase II Study of the Combination of Subcutaneous Blinatumomab and Olverembatinib in Patients With Philadelphia Chromosome (ph)-Positive and/or BCR::ABL1 Positive Acute Lymphoblastic Leukemia (ALL) Blinatumomab, olverembatinib - Phase II Clinical Trial, Blinatumomab | Phase 2 | Not yet recruiting | M.D. Anderson Cancer Center | 60 | 2027-01-27 | 2026-10-07 |
| Observational Safety Study in Women With Neuromyelitis Optica Spectrum Disorder (NMOSD) Exposed to UPLIZNA® During Pregnancy UPLIZNA - Neuromyelitis Optica Spectrum Disorder, Pregnancy Related | Recruiting | Amgen | 60 | 2027-01-15 | 2026-10-29 | |
| Subcutaneous Blinatumomab Plus Ponatinib for BCR-ABL+ B-ALL Treatment with blinatumomab given subcutaneously. - Acute Lymphoblastic Leukemia (ALL) Philadelphia Chromosome-positive (Ph+), BCR-ABL Positive Acute Lymphoblastic Leukemia | Phase 2 | Not yet recruiting | University of Alberta | 80 | 2027-01-02 | 2026-08-12 |
| Tarlatamab and Durvalumab vs. Durvalumab Alone for Limited-Stage-Small Cell Lung Cancer Tarlatamab, Durvalumab - Limited Stage Small-Cell Lung Cancer | Phase 3 | Not yet recruiting | PrECOG, LLC. | 430 | 2027-01-01 | 2026-06-09 |
| A Trial of Inebilizumab in Participants With Autoimmune Hepatitis Inebilizumab, Placebo, Standard of Care - Autoimmune Hepatitis, AIH | Phase 3 | Recruiting | Amgen | 180 | 2026-12-18 | 2026-11-03 |
| Mechanistic Clinical Trial of PCSK9 Inhibition for AAA Evolocumab, Placebo - Abdominal Aortic Aneurysm | Early Phase 1 | Not yet recruiting | University of Pennsylvania | 44 | 2026-12-01 | 2026-04-20 |
| A Phase IB Trial of Subcutaneous Blinatumomab in Combination With Revumenib for Patients With KMT2A-rearranged Acute Lymphoblastic Leukemia Revumenib, Blinatumomab - Blinatumomab, Revumenib | Phase 1 | Not yet recruiting | M.D. Anderson Cancer Center | 20 | 2026-11-18 | 2026-08-12 |
| Comparing the Extent to Which Apremilast is Made Available in the Body After Administration as an Extended-release or Immediate-release Formulation Apremilast XR, Apremilast IR - Psoriasis, Arthritis, Psoriatic | Phase 1 | Not yet recruiting | Amgen | 114 | 2026-11-18 | 2026-11-02 |
| Comparing the Extent to Which Maridebart Cafraglutide is Made Available in the Body of Participants Living With Overweight or Obesity After Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) Maridebart cafraglutide - Obesity, Overweight | Phase 1 | Recruiting | Amgen | 180 | 2026-11-13 | 2026-11-02 |
| Maridebart Cafraglutide Versus Semaglutide in Participants With Type 2 Diabetes Maridebart cafraglutide, Semaglutide - Diabetes Mellitus, Type 2 | Phase 3 | Not yet recruiting | Amgen | 1300 | 2026-11-02 | 2026-10-08 |
| Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Inebilizumab in Pediatric Participants With IgG4-RD Inebilizumab - Immunoglobulin G4-related Disease | Phase 2 | Not yet recruiting | Amgen | 15 | 2026-10-31 | 2026-08-27 |
| Home Self-administration of Maridebart Cafraglutide With Autoinjector in Adults Living With Obesity or Overweight Maridebart cafraglutide, Autoinjector - Obesity, Overweight | Phase 3 | Not yet recruiting | Amgen | 230 | 2026-10-28 | 2026-10-13 |
| Comparing the Extent to Which Two Maridebart Cafraglutide Drug Products Are Made Available in the Body After a Single Subcutaneous Dose Maridebart Cafraglutide - Overweight, Obesity | Phase 1 | Not yet recruiting | Amgen | 340 | 2026-10-12 | 2026-09-22 |
| Improving Implementation of Guideline-Recommended LDL-C Management in High-Risk Cardiovascular Patients ASCVD | Not yet recruiting | Cardiology Consultants of Philadelphia | 2500 | 2026-10-01 | 2026-10-23 | |
| A Phase 3 Study of Inebilizumab in Participants With Primary Membranous Nephropathy Inebilizumab, Tacrolimus - Glomerulonephritis, Membranous | Phase 3 | Recruiting | Amgen | 159 | 2026-10-01 | 2026-10-01 |
| LuX: Xaluritamig in Participants With Metastatic Castrate Resistant Prostate Cancer and Suboptimal Response to Lutetium 177 Vipivotide Tetraxetan Xaluritamig - Prostate Cancer, Metastatic Castrate Resistant Prostate Cancer | Phase 2 | Not yet recruiting | Thomas Jefferson University | 30 | 2026-10-01 | 2026-08-14 |
| Comparing the Extent to Which Romosozumab (AMG 785) is Made Available in the Body When Administered as a Single SC Injection or as 2 SC Injections Romosozumab - Healthy Participants | Phase 1 | Recruiting | Amgen | 308 | 2026-09-22 | 2026-10-13 |
| A Study of Inotuzumab and Blinatumomab in People With B-cell Acute Lymphoblastic Leukemia Blinatumomab Injection - B-cell Acute Lymphoblastic Leukemia, B-Cell Acute Lymphoblastic Leukemia, Adult | Phase 1 / Phase 2 | Not yet recruiting | Memorial Sloan Kettering Cancer Center | 26 | 2026-09-01 | 2026-08-11 |
Showing 20 of 1587. Sign in to see all of them.
Neoplasms (112) · Multiple Myeloma (89) · Psoriasis (71) · Anemia (69) · Breast Neoplasms (69) · Colorectal Neoplasms (69) · Arthritis, Rheumatoid (60) · Carcinoma, Non-Small-Cell Lung (59) · Renal Insufficiency, Chronic (56) · Osteoporosis (46) · Neoplasm Metastasis (41) · Hypercholesterolemia (39) · Obesity (36) · Recurrence (36) · Hyperparathyroidism, Secondary (35)
Panitumumab (98) · Denosumab (87) · carfilzomib (79) · Etanercept (77) · Darbepoetin alfa (75) · Dexamethasone (68) · evolocumab (62) · apremilast (58) · blinatumomab (47) · Paclitaxel (43) · Carboplatin (40) · Cyclophosphamide (39) · sotorasib (38) · pegfilgrastim (37) · Cinacalcet (36)
United States (891) · Canada (293) · Germany (288) · Spain (277) · France (268) · Australia (218) · Poland (218) · Italy (216) · United Kingdom (210) · Belgium (207) · Czechia (152) · Netherlands (152) · Japan (150) · Hungary (142) · Greece (132)
Corinne Haioun, MD (4) · Brian GM Durie, MD (3) · John Rieth, MD (3) · Robert Bissonnette, MD (3) · Andrew Menzies-Gow, MD (2) · Antonio Arrivi, MD (2) · Aram Hezel, MD (2) · Benjamin Derman, MD (2)
PMID 37316690, PMID 33078867, PMID 38979716, PMID 24144944, PMID 36791280, PMID 42825996, PMID 34928306, PMID 41671463, PMID 19671919, PMID 22070868, PMID 26049686, PMID 26373676, PMID 37185961, PMID 18328118, PMID 22961727, PMID 22975218, PMID 23975226, PMID 26093811, PMID 29627309, PMID 30018799, PMID 31077258, PMID 31776637, PMID 31909868, PMID 33051459, PMID 34213592, PMID 34252375, PMID 34301173, PMID 34536218, PMID 35820631, PMID 35978286, PMID 36702146, PMID 39604046, PMID 16710026, PMID 18227526, PMID 18242413, PMID 18316791, PMID 20512995, PMID 20533525, PMID 20838998, PMID 20943783, PMID 20952478, PMID 20957659, PMID 21660636, PMID 21917874, PMID 22152181, PMID 22494019, PMID 22508812, PMID 23986513, PMID 24014831, PMID 25773607
2023 (30), 2014 (29), 2017 (25), 2015 (19), 2018 (18), 2016 (16), 2009 (14), 2019 (14), 2025 (11), 2008 (6), 2005 (3), M01RR001032 (2), R01DK058785 (2), 1UF1AG046150-01 (1), 2004 (1)